Literature DB >> 30814254

Crystal structure of the WFIKKN2 follistatin domain reveals insight into how it inhibits growth differentiation factor 8 (GDF8) and GDF11.

Jason C McCoy1, Ryan G Walker1, Nathan H Murray1, Thomas B Thompson2.   

Abstract

Growth differentiation factor 8 (GDF8; also known as myostatin) and GDF11 are closely related members of the transforming growth factor β (TGF-β) family. GDF8 strongly and negatively regulates skeletal muscle growth, and GDF11 has been implicated in various age-related pathologies such as cardiac hypertrophy. GDF8 and GDF11 signaling activities are controlled by the extracellular protein antagonists follistatin; follistatin-like 3 (FSTL3); and WAP, follistatin/kazal, immunoglobulin, Kunitz, and netrin domain-containing (WFIKKN). All of these proteins contain a follistatin domain (FSD) important for ligand binding and antagonism. Here, we investigated the structure and function of the FSD from murine WFIKKN2 and compared it with the FSDs of follistatin and FSTL3. Using native gel shift and surface plasmon resonance analyses, we determined that the WFIKKN2 FSD can interact with both GDF8 and GDF11 and block their interactions with the type II receptor activin A receptor type 2B (ActRIIB). Further, we solved the crystal structure of the WFIKKN2 FSD to 1.39 Å resolution and identified surface-exposed residues that, when substituted with alanine, reduce antagonism of GDF8 in full-length WFIKKN2. Comparison of the WFIKKN2 FSD with those of follistatin and FSTL3 revealed differences in both the FSD structure and position of residues within the domain that are important for ligand antagonism. Taken together, our results indicate that both WFIKKN and follistatin utilize their FSDs to block the type II receptor but do so via different binding interactions.
© 2019 McCoy et al.

Entities:  

Keywords:  GDF11; GDF8; WFIKKN; X-ray crystallography; antagonism; follistatin; inhibitor; muscle development; myostatin; protein structure; structural biology; tissue homeostasis; transforming growth factor beta (TGF-β)

Mesh:

Substances:

Year:  2019        PMID: 30814254      PMCID: PMC6484119          DOI: 10.1074/jbc.RA118.005831

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  62 in total

1.  The role of follistatin domains in follistatin biological action.

Authors:  Henry T Keutmann; Alan L Schneyer; Yisrael Sidis
Journal:  Mol Endocrinol       Date:  2003-10-16

2.  Crystal structure of trypsin-turkey egg white inhibitor complex.

Authors:  B Syed Ibrahim; Vasantha Pattabhi
Journal:  Biochem Biophys Res Commun       Date:  2004-01-02       Impact factor: 3.575

3.  MolProbity: More and better reference data for improved all-atom structure validation.

Authors:  Christopher J Williams; Jeffrey J Headd; Nigel W Moriarty; Michael G Prisant; Lizbeth L Videau; Lindsay N Deis; Vishal Verma; Daniel A Keedy; Bradley J Hintze; Vincent B Chen; Swati Jain; Steven M Lewis; W Bryan Arendall; Jack Snoeyink; Paul D Adams; Simon C Lovell; Jane S Richardson; David C Richardson
Journal:  Protein Sci       Date:  2017-11-27       Impact factor: 6.725

4.  Characterization of a novel Kazal-type serine proteinase inhibitor of Arabidopsis thaliana.

Authors:  Sebastián Pariani; Marisol Contreras; Franco R Rossi; Valeria Sander; Mariana G Corigliano; Francisco Simón; María V Busi; Diego F Gomez-Casati; Fernando L Pieckenstain; Vilma G Duschak; Marina Clemente
Journal:  Biochimie       Date:  2016-02-04       Impact factor: 4.079

5.  A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy.

Authors:  Jerry R Mendell; Zarife Sahenk; Vinod Malik; Ana M Gomez; Kevin M Flanigan; Linda P Lowes; Lindsay N Alfano; Katherine Berry; Eric Meadows; Sarah Lewis; Lyndsey Braun; Kim Shontz; Maria Rouhana; Kelly Reed Clark; Xiomara Q Rosales; Samiah Al-Zaidy; Alessandra Govoni; Louise R Rodino-Klapac; Mark J Hogan; Brian K Kaspar
Journal:  Mol Ther       Date:  2014-10-17       Impact factor: 11.454

6.  A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy.

Authors:  Kathryn R Wagner; James L Fleckenstein; Anthony A Amato; Richard J Barohn; Katharine Bushby; Diana M Escolar; Kevin M Flanigan; Alan Pestronk; Rabi Tawil; Gil I Wolfe; Michelle Eagle; Julaine M Florence; Wendy M King; Shree Pandya; Volker Straub; Paul Juneau; Kathleen Meyers; Cristina Csimma; Tracey Araujo; Robert Allen; Stephanie A Parsons; John M Wozney; Edward R Lavallie; Jerry R Mendell
Journal:  Ann Neurol       Date:  2008-05       Impact factor: 10.422

7.  Molecular characterization of latent GDF8 reveals mechanisms of activation.

Authors:  Ryan G Walker; Jason C McCoy; Magdalena Czepnik; Melanie J Mills; Adam Hagg; Kelly L Walton; Thomas R Cotton; Marko Hyvönen; Richard T Lee; Paul Gregorevic; Craig A Harrison; Thomas B Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-18       Impact factor: 11.205

8.  Treatment with rGDF11 does not improve the dystrophic muscle pathology of mdx mice.

Authors:  Fabrizio Rinaldi; Yu Zhang; Ricardo Mondragon-Gonzalez; Jeffrey Harvey; Rita C R Perlingeiro
Journal:  Skelet Muscle       Date:  2016-06-14       Impact factor: 4.912

9.  Structural basis for potency differences between GDF8 and GDF11.

Authors:  Ryan G Walker; Magdalena Czepnik; Erich J Goebel; Jason C McCoy; Ana Vujic; Miook Cho; Juhyun Oh; Senem Aykul; Kelly L Walton; Gauthier Schang; Daniel J Bernard; Andrew P Hinck; Craig A Harrison; Erik Martinez-Hackert; Amy J Wagers; Richard T Lee; Thomas B Thompson
Journal:  BMC Biol       Date:  2017-03-03       Impact factor: 7.431

10.  Growth Differentiation Factor 11 treatment leads to neuronal and vascular improvements in the hippocampus of aged mice.

Authors:  Ceren Ozek; Richard C Krolewski; Sean M Buchanan; Lee L Rubin
Journal:  Sci Rep       Date:  2018-11-23       Impact factor: 4.379

View more
  7 in total

1.  Structural biology of the TGFβ family.

Authors:  Erich J Goebel; Kaitlin N Hart; Jason C McCoy; Thomas B Thompson
Journal:  Exp Biol Med (Maywood)       Date:  2019-10-09

2.  Comprehensive Endogenous Tagging of Basement Membrane Components Reveals Dynamic Movement within the Matrix Scaffolding.

Authors:  Daniel P Keeley; Eric Hastie; Ranjay Jayadev; Laura C Kelley; Qiuyi Chi; Sara G Payne; Jonathan L Jeger; Brenton D Hoffman; David R Sherwood
Journal:  Dev Cell       Date:  2020-06-24       Impact factor: 12.270

3.  Generation of Heritable Prominent Double Muscle Buttock Rabbits via Novel Site Editing of Myostatin Gene Using CRISPR/Cas9 System.

Authors:  Yalin Zheng; Yu Zhang; Liyan Wu; Hasan Riaz; Zhipeng Li; Deshun Shi; Saif Ur Rehman; Qingyou Liu; Kuiqing Cui
Journal:  Front Vet Sci       Date:  2022-05-20

4.  Characterization of tolloid-mediated cleavage of the GDF8 procomplex.

Authors:  Jason C McCoy; Erich J Goebel; Thomas B Thompson
Journal:  Biochem J       Date:  2021-05-14       Impact factor: 3.857

Review 5.  Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs.

Authors:  Buel D Rodgers; Christopher W Ward
Journal:  Endocr Rev       Date:  2022-03-09       Impact factor: 25.261

6.  Refining the Camelus dromedarius Myostatin Gene Polymorphism through Worldwide Whole-Genome Sequencing.

Authors:  Silvia Bruno; Vincenzo Landi; Gabriele Senczuk; Samantha Ann Brooks; Faisal Almathen; Bernard Faye; Suheil Semir Bechir Gaouar; Mohammed Piro; Kwan Suk Kim; Xavier David; André Eggen; Pamela Burger; Elena Ciani
Journal:  Animals (Basel)       Date:  2022-08-14       Impact factor: 3.231

7.  Mutational Analysis of the Putative Anti-Müllerian Hormone (AMH) Binding Interface on its Type II Receptor, AMHR2.

Authors:  Kaitlin N Hart; David Pépin; Magdalena Czepnik; Patricia K Donahoe; Thomas B Thompson
Journal:  Endocrinology       Date:  2020-07-01       Impact factor: 4.736

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.